Causes of Neuro Regression at 2 years

1. Introduction

Neuroregression is the loss of previously acquired developmental milestones.

2. Genetic and Neurocutaneous Syndromes (Top Differentials)

• Rett Syndrome (MECP2 mutation):
  • Classic Course: Normal development until 6–18 months, followed by rapid regression.
  • Features: Loss of purposeful hand skills, development of hand stereotypies (wringing/washing), loss of verbal skills, gait ataxia, and acquired microcephaly.
• Neurofibromatosis Type 1 (NF1): Can present with regression due to optic pathway gliomas or vascular (Moyamoya) changes, though less common as primary regression.
• Tuberous Sclerosis: Regression due to intractable epilepsy (Infantile spasms/LGS) or SEGA.

3. Neurodegenerative Disorders (Metabolic)

Classified based on primary site of pathology:

A. Grey Matter Disorders (Poliodystrophies)

• Features: Early seizures, visual loss, cognitive decline. Motor signs appear late.
• Late Infantile Neuronal Ceroid Lipofuscinosis (NCL - Jansky-Bielschowsky): Onset 2–4 years (early cases at 18 months). Seizures, ataxia, retinal degeneration.
• GM1 / GM2 Gangliosidosis (Tay-Sachs/Sandhoff): Late-onset variants can present in the second year with regression, startle response, and cherry-red spot.
• Menkes Disease: Neuroregression with sparse "kinky" hair (usually earlier onset, but milder variants exist).

B. White Matter Disorders (Leukodystrophies)

• Features: Early spasticity, ataxia, UMN signs. Cognition affected later.
• Late Infantile Metachromatic Leukodystrophy (MLD): Onset 1–2 years. Gait disturbance (ataxia/spasticity) is the first sign, followed by global regression.
• Krabbe Disease (Late Infantile): Irritability, stiffness, regression.
• Canavan Disease: Macrocephaly, hypotonia evolving to spasticity.

C. Mitochondrial Disorders

• Leigh Syndrome (Subacute Necrotizing Encephalomyelopathy):
  • Trigger: Often precipitated by a viral infection/fever.
  • Features: Ataxia, dystonia, respiratory irregularity, regression.

4. Epileptic Encephalopathies

• Lennox-Gastaut Syndrome (LGS): Evolution from West Syndrome or de novo. Multiple seizure types + cognitive regression.
• Landau-Kleffner Syndrome (Acquired Epileptic Aphasia):
  • Specific Regression: Loss of language (verbal auditory agnosia) in a previously speaking child.
  • Age: Usually 3–7 years, but can start as early as 18–24 months.

5. Pervasive Developmental Disorders

• Autism Spectrum Disorder (Regressive Type):
  • Presentation: ~30% of children with ASD show regression between 15 and 24 months.
  • Features: Loss of language ("words lost"), loss of social smile/eye contact, social withdrawal. Motor milestones are usually preserved.

6. Infectious and Post-Infectious

• HIV Encephalopathy: Progressive loss of milestones, spastic diplegia, and failure to thrive.
• Subacute Sclerosing Panencephalitis (SSPE): Usually school age, but can present rapidly in toddlers if primary measles infection occurred in infancy (<1 year). Features: Behavioral changes $\to$ Myoclonus $\to$ Regression.
• Chronic Meningitis: Tuberculous meningitis (TBM) sequelae or indolent presentation.

7. Toxic and Nutritional

• Lead Poisoning (Plumbism):
  • History: Pica, living in old housing.
  • Features: Anemia, irritability, aggressive behavior, loss of skills, encephalopathy.
• Vitamin B12 Deficiency: Infantile Tremor Syndrome (usually earlier, but untreated cases regress).

8. Structural and Vascular

• Intracranial Space Occupying Lesion: Craniopharyngioma, Posterior fossa tumors (medulloblastoma) causing hydrocephalus.
• Moyamoya Disease: Recurrent TIA/strokes leading to stepwise regression.

9. Approach Summary Table

Neuro-regression with HSM

• The Syndrome: The combination of Neuroregression (loss of milestones) and Hepatosplenomegaly (HSM) strongly points towards a Lysosomal Storage Disorder (LSD) or a Neuro-metabolic disorder.
• Key exclusion: Pure leukodystrophies (like MLD, Krabbe) and pure poliodystrophies (like Tay-Sachs, Neuronal Ceroid Lipofuscinosis) typically do not have organomegaly.
• Anatomic Localization: Since regression is global (cognitive + motor) with organ involvement, this is a multi-system metabolic disease.

Differential Diagnosis

The differentials can be grouped based on the class of metabolic defect.

A. Sphingolipidoses (Lipid Storage Disorders)

• Niemann-Pick Disease Type C (NPC):
  • Classic Presentation: A toddler with ataxia, frequent falls, cognitive regression, and splenomegaly (or HSM).
  • Key Sign: Vertical Supranuclear Gaze Palsy (VSGP) – inability to look up/down voluntarily.
  • Other: Gelastic cataplexy (loss of tone with laughter).
• Niemann-Pick Disease Type A (NPA):
  • Usually presents in infancy (3–6 months) with failure to thrive and rapid regression. Most die by 2–3 years. Less likely for a 6-month history starting at 1.5 years, but possible in intermediate forms.
  • Key Sign: Cherry Red Spot (50%).
• Gaucher Disease Type 2 (Acute) / Type 3 (Chronic):
  • Type 2: Infantile, bulbar palsy, stridor, rapid death (unlikely here).
  • Type 3 (Subacute/Juvenile): Regression, seizures, Oculomotor Apraxia (horizontal gaze palsy), and Massive Splenomegaly.
• GM1 Gangliosidosis (Late Infantile):
  • Onset 1–3 years. Gait disturbance, regression.
  • Features: Coarse facies, HSM, dysostosis multiplex (skeletal changes).
• Sandhoff Disease (GM2 Gangliosidosis variant):
  • Clinically similar to Tay-Sachs (startle response, cherry red spot) BUT has Hepatosplenomegaly. (Tay-Sachs has no organomegaly).

B. Mucopolysaccharidoses (MPS)

• MPS I (Hurler Syndrome):
  • Regression often starts after 1 year.
  • Features: Coarse facies, HSM, Corneal Clouding, Dysostosis Multiplex (claw hand, gibbus).
• MPS II (Hunter Syndrome):
  • X-linked (Males). Similar to Hurler but Clear Corneas.
• MPS III (Sanfilippo Syndrome):
  • Profound Regression: CNS features dominate (hyperactivity, sleep issues, regression).
  • Mild Somatic: HSM and coarsening are mild compared to MPS I/II.

C. Other Metabolic/Genetic Causes

• Mucolipidosis (I-Cell Disease): Severe gingival hypertrophy, coarse features, HSM.
• Fucosidosis / Mannosidosis: Rare glycoprotein disorders with coarse features and HSM.

D. Infectious / Non-Metabolic (Rule Out)

• HIV Encephalopathy: Can present with developmental regression (loss of milestones), failure to thrive, and HSM/lymphadenopathy.

Diagnostic Approach

Step 1: Detailed History

• Onset: Is it insidious (metabolic) or stepwise (vascular)?
• Family History: Consanguinity (Autosomal Recessive LSDs), male deaths (X-linked Hunter).
• Specific Symptoms:
  • Vision/Hearing loss: MPS, Gangliosidosis.
  • Startle response (Hyperacusis): Sandhoff.
  • Seizures: Gaucher type 3, GM1.

Step 2: Targeted Clinical Examination

The exam helps narrow the specific enzyme defect.

Step 3: Screening Investigations

1. Hemogram & Blood Film:
   • Vacuolated Lymphocytes: Suggests Niemann-Pick, Batten disease, or Gangliosidosis.
   • Alder-Reilly Anomalies (Granules): Suggests MPS.
   • Pancytopenia: Suggests hypersplenism (Gaucher).
2. Skeletal Survey (X-rays):
   • Look for Dysostosis Multiplex: Thickened skull, J-shaped sella, oar-shaped ribs, anterior beaking of vertebrae, proximal pointing of metacarpals. (Positive in MPS, GM1, Mucolipidosis).
3. Abdominal Ultrasound: Confirm liver texture and spleen size.
4. Ophthalmology: Slit lamp (clouding) and Fundoscopy (cherry red spot/optic atrophy).
5. MRI Brain:
   • Usually shows atrophy or white matter changes (nonspecific).
   • Thalamic Hyperintensity: GM1 / GM2 gangliosidosis.

Step 4: Confirmatory Testing (The Gold Standard)

Based on the clinical phenotype (Phenotype-Genotype correlation).

• If Coarse Facies + Dysostosis:
  • Urine GAGs (Glycosaminoglycans): Screening test for MPS.
  • Enzyme Assay: Iduronidase (MPS I), Iduronate sulfatase (MPS II), Heparan sulfamidase (MPS III).
• If Cherry Red Spot / Eye Signs:
  • Enzyme Assay (Leukocytes):
    • Beta-Galactosidase (GM1).
    • Hexosaminidase A & B (Sandhoff).
    • Sphingomyelinase (Niemann-Pick A/B).
    • Glucocerebrosidase (Gaucher).
• If Niemann-Pick C Suspected (VSGP present):
  • Biomarker: Plasma Oxysterols (Lyso-SM-509).
  • Filipin Staining: (Skin fibroblast) - historical test for cholesterol accumulation.
  • Genetic Testing: NPC1 or NPC2 gene sequencing.
• Bone Marrow Aspiration (Historical/Adjunct):
  • Gaucher Cells: "Crumpled tissue paper" cytoplasm.
  • Niemann-Pick Cells: "Foam cells" (Sea-blue histiocytes).

Summary of Management

• Gaucher Type 1/3: Enzyme Replacement Therapy (ERT) - Imiglucerase.
• MPS I/II: ERT (Laronidase/Idursulfase) + Hematopoietic Stem Cell Transplant (HSCT) for CNS protection (in Hurler).
• Niemann-Pick C: Miglustat (Substrate reduction therapy) stabilizes neurological progression.
• Supportive: Seizure control, physiotherapy, nutritional support.